Ontology highlight
ABSTRACT: Background
Fostemsavir, a first-in-class attachment inhibitor that binds to the viral envelope protein gp120, is approved for heavily treatment-experienced persons with HIV-1 with limited treatment options. We explored changes in immunologic and coagulopathy parameters in the BRIGHTE study: a phase 3 trial that evaluated fostemsavir plus optimized background therapy in heavily treatment-experienced adults with multidrug-resistant HIV-1.Methods
CD4+ T-cell count, CD4+/CD8+ ratio, soluble CD14, soluble CD163, and D-dimer levels were measured through 96 weeks in participants with 1 or 2 fully active antiretroviral agents available at screening. No formal statistical analyses were performed.Results
Among 272 participants, increases were observed from baseline to week 96
SUBMITTER: Clark A
PROVIDER: S-EPMC11372475 | biostudies-literature | 2024 Sep
REPOSITORIES: biostudies-literature